Altimmune Stock Forecast
NASDAQ: ALTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 8, 11:02 AM ET
ALT analyst consensus
Consensus (10 analysts)
strong_buy
Avg. price target
$17.11+564.47%
- Strong buy 2
- Buy 7
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 10 Wall Street analysts covering Altimmune (2026-10-08), 9 rate the stock a buy or strong buy, 1 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $17.11, with a high estimate of $28.00 and a low estimate of $11.00. The average target implies upside of 564.5% from the current price of $2.58.
The spread between the highest and lowest targets is 154.5%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for ALT.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 2 | 20% |
| Buy | 7 | 70% |
| Hold | 1 | 10% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $11.00 | +327.18% |
| Average target | $17.11 | +564.47% |
| High target | $28.00 | +987.38% |